trending Market Intelligence /marketintelligence/en/news-insights/trending/lpxvwCjVws3zRQEQTLN8_A2 content esgSubNav
In This List

Vistin Pharma board proposes dividend

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond


Vistin Pharma board proposes dividend

The Vistin Pharma ASA board proposed an extraordinary dividend of 7 Norwegian kroner per share after completing the sale of its opioids and tablet manufacturing business to TPI Enterprises Ltd.

The company expects a positive net cash effect between 140 million kroner to 150 million kroner, before any transaction costs, from the sale of the assets.

As of Oct. 6, US$1 was equivalent to 8.01 Norwegian kroner.